SOLIGENIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SOLIGENIX, INC. (SNGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-07
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 0.00 shares.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 670.09K shares, a 285.68% increase from fiscal 2024.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 173.74K shares, a 280.05% increase from fiscal 2023.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 45.72K shares, a 17.97% decline from fiscal 2022.
- SOLIGENIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 55.73K shares, a 69.26% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-08 | ||||
| 2025-12-31 | 670.09K shares 10-K · filed 2026-03-31 | ||||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-08 | ||||
| 2024-12-31 | 173.74K shares 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-08 | ||||
| 2023-12-31 | 45.72K shares 10-K · filed 2025-03-21 | 731.54K shares 10-K · filed 2024-03-15 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-08 | ||||
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | 55.73K shares 10-K · filed 2024-03-15 | ||||
| 2021-12-31 | 32.92K shares 10-K · filed 2023-03-31 | 452.19K shares 10-K · filed 2022-03-29 | |||
| 2020-12-31 | 520.81K shares 10-K · filed 2022-03-29 | ||||
| 2019-12-31 | 596.74K shares 10-K · filed 2021-03-30 | ||||
| 2015-09-30 | 125.34K shares 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |